Alkhalifa, A.E.; Al Mokhlf, A.; Ali, H.; Al-Ghraiybah, N.F.; Syropoulou, V.
Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection. J. Pers. Med. 2025, 15, 437.
https://doi.org/10.3390/jpm15090437
AMA Style
Alkhalifa AE, Al Mokhlf A, Ali H, Al-Ghraiybah NF, Syropoulou V.
Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection. Journal of Personalized Medicine. 2025; 15(9):437.
https://doi.org/10.3390/jpm15090437
Chicago/Turabian Style
Alkhalifa, Amer E., Abdulrahman Al Mokhlf, Hande Ali, Nour F. Al-Ghraiybah, and Vasiliki Syropoulou.
2025. "Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection" Journal of Personalized Medicine 15, no. 9: 437.
https://doi.org/10.3390/jpm15090437
APA Style
Alkhalifa, A. E., Al Mokhlf, A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V.
(2025). Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease: Evidence, ARIA Risk, and Precision Patient Selection. Journal of Personalized Medicine, 15(9), 437.
https://doi.org/10.3390/jpm15090437